A seeding trial or marketing trial is a form of marketing, conducted in the name of research, designed to target product sampling towards selected consumers. In the marketing research field, seeding is the process of allocating marketing to specific customers, or groups of customers, in order to stimulate the internal dynamics of the market, and enhance the diffusion process. In medicine, seeding trials are clinical trials or research studies in which the primary objective is to introduce the concept of a particular medical intervention—such as a pharmaceutical drug or medical device—to physicians, rather than to test a scientific hypothesis. To create loyalty and advocacy towards a brand, seeding trials take advantage of opinion leadership to enhance sales, capitalizing on the Hawthorne Effect. In a seeding trial, the brand provides potential opinion leaders with the product for free, aiming to gain valuable pre-market feedback and also to build support among the testers, creating influential word-of-mouth advocates for the product. By involving the opinion leaders as testers, effectively inviting them to be an extension of the marketing department, companies can create "a powerful sense of ownership among the clients, customers or consumers that count" by offering engaging the testers in a research dialogue. Seeding trials in medicine are not illegal but are considered unethical because they "deceive investigators, clinicians, and patients, subverting the scientific process".
In medicine Seeding trials to promote a medical intervention were described as "trials of approved drugs [that] appear to serve little or no scientific purpose" and "thinly veiled attempts to entice doctors to prescribe a new drug being marketed by the company" in a special article in the New England Journal of Medicine. The article, whose authors included U.S. Food and Drug Administration commissioner David Aaron Kessler, also described a number of characteristics common to seeding trials:
The trial is of an intervention with many competitors Use of a trial design unlikely to achieve its stated scientific aims (e.g., un-blinded, no control group, no placebo) Recruitment of physicians as trial investigators because they commonly prescribe similar medical interventions rather than for their scientific merit Disproportionately high payments to trial investigators for relatively little work Sponsorship is from a company's sales or marketing budget rather than from research and development Little requirement for valid data collection An analysis of 34,398 industry-funded phase 3 and 4 trials posted on ClinicalTrials.gov from 1998 to 2024, covering seven therapeutic areas with confirmed seeding trials, found that 204 (0.59%) displayed marketing-driven characteristics when criteria such as low patient-to-site ratios and limited independent oversight were applied . In a seeding trial, doctors and their patients are given free access to a drug and exclusive information and services to use the drug effectively. Additionally, participating physicians are often given financial remuneration and a chance to be a co-author on a resulting scientific publication. By triggering the Hawthorne effect, physicians become "opinion-leading word-of-mouth advocates". This practice has been shown to be effective. Seeding trials are not illegal, but such practices are considered unethical. The obfuscation of true trial objectives (primarily marketing) prevents the proper establishment of informed consent for patient decisions. Additionally, trial physicians are not informed of the hidden trial objectives, which may include the physicians themselves being intended study subjects (such as in undisclosed evaluations of prescription practices). Seeding trials may also utilize inappropriate promotional rewards, which may exert undue influence or coerce desirable outcomes.
Examples Documents released during a court case indicate that the Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness (ADVANTAGE) trial of Vioxx conducted by Merck may have been a seeding trial, with the intention being to introduce the drug to physicians rather than test its efficacy. It appears Merck knew about the potential criticism they would face; an internal email suggested: "It may be a seeding study, but let's not call it that in our internal documents". The 2003 study was originally published in the Annals of Internal Medicine but was strongly criticized for its deception by the journal's editors in a 2008 editorial, calling for greater responsibility in academia to end the practice of "marketing in the guise of science". In the STEPS trial Pfizer presented their drug Neurontin in a way that merged pharmaceutical marketing with research. This trial and other practices led to the company's loss in Franklin v. Parke-Davis.
Regulatory oversight No regulatory body currently conducts prospective monitoring for marketing-driven trial protocols; detection has depended on whistleblowers and litigation, which tend to uncover egregious cases rather than ambiguous ones . Regulatory standards vary across jurisdictions: the European Medicines Agency mandates registration and results reporting through EudraCT, while systems in low- and middle-income countries often remain less stringent, creating vulnerabilities that sponsors can exploit. Kang, Lin, and Chang argue that international harmonisation through the WHO and the International Council for Harmonisation is needed to prevent such regulatory arbitrage, and that platforms tracking industry payments to physicians, such as the U.S. Open Payments database, should be mandated in other jurisdictions.
… excerpt ends here. Continue reading the full article.
